Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Transactions of the Royal Society of Tropical Medicine and Hygiene|December 3, 2019
Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patientsJackson K Mukonzo, Allan Kengo, Bisaso Kutesa, et al.
Pharmaceuticals (Basel, Switzerland)|April 30, 2021
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni InfectionOmary Mashiku Minzi, Rajabu Hussein Mnkugwe, Eliford Ngaimisi, et al.
Scientific Reports|July 7, 2021
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillationAlenka Mavri, Nina Vene, Mojca Božič-Mijovski, et al.
European Journal of Clinical Pharmacology|May 30, 2019
Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillationMarko Miklič, Alenka Mavri, Nina Vene, et al.
Plos One|September 14, 2011
Studies on the antibacterial effects of statins--in vitro and in vivoPeter Bergman, Charlotte Linde, Katrin Pütsep, et al.
Antimicrobial Agents and Chemotherapy|June 4, 2014
Posaconazole concentrations in human tissues after allogeneic stem cell transplantationOla Blennow, Erik Eliasson, Tommy Pettersson, et al.
Basic & Clinical Pharmacology & Toxicology|May 19, 2015
Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial FibrillationPetra Šinigoj, Rickard E Malmström, Nina Vene, et al.
European Journal of Clinical Pharmacology|April 13, 2016
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillationFadiea Al-Aieshy, Rickard E Malmström, Jovan Antovic, et al.
Thrombosis Research|August 31, 2014
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillationMika Skeppholm, Paul Hjemdahl, Jovan P Antovic, et al.
BMJ Case Reports|December 17, 2015
Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case studyInti Peredo, Anders Helldén, Nina Wolmer-Solberg, et al.
Pageof 6